Silexion Therapeutics
SLXN
3 hedge funds and large institutions have $281K invested in Silexion Therapeutics in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.
0.05% more ownership
Funds ownership: 0.01% → 0.06% (+0.05%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
40% less funds holding
Funds holding: 5 → 3 (-2)
54% less capital invested
Capital invested by funds: $613K → $281K (-$332K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$37.3K |
| 2 |
HF
HRT Financial
New York
|
+$5.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$14K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$7.94K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WCM
1
Wildcat Capital Management
New York
| $228K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $29.9K | +$37.3K | +88 | +800% |
|
|
HF
3
HRT Financial
New York
| $23K | +$5.09K | +12 | +18% |
|
|
VF
4
Virtu Financial
New York
| – | -$14K | -20 | Closed |
|
|
TSS
5
Two Sigma Securities
New York
| – | -$7.94K | -11 | Closed |
|
SLXN Hedge Fund Activity: Q4 2024 in Review
3 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics (SLXN) for Q4 2024, worth a combined $281K — down 54% from $613K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SLXN and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $37.3K. The largest seller was Virtu Financial, exiting entirely with an estimated $14K sold.
- 3 institutional investors held Silexion Therapeutics (SLXN) as of Q4 2024, down from 5 in Q3 2024.
- Funds reported $281K of Silexion Therapeutics stock for Q4 2024, down 54% quarter-over-quarter.
- 0 funds opened new Silexion Therapeutics positions in Q4 2024 and 2 closed out, a net change of -2 holders.
- The largest Silexion Therapeutics buyer in Q4 2024 was UBS Group, an estimated $37.3K added.
- The largest Silexion Therapeutics seller in Q4 2024 was Virtu Financial, an estimated $14K sold.
Based on aggregated 13F filings for Q4 2024.